Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the releva...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Genome Res
Hlavní autoři: Kim, Wonjoo, Lee, Sangeun, Kim, Han Sang, Song, Minjung, Cha, Yong Hoon, Kim, Young-Hoon, Shin, Jeonghong, Lee, Eun-Seo, Joo, Yeonsoo, Song, Jae J., Choi, Eun Ju, Choi, Jae W., Lee, Jinu, Kang, Moonkyung, Yook, Jong In, Lee, Min Goo, Kim, Yeon-Soo, Paik, Soonmyung, Kim, Hyongbum (Henry)
Médium: Artigo
Jazyk:Inglês
Vydáno: Cold Spring Harbor Laboratory Press 2018
Témata:
Method
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://ncbi.nlm.nih.gov/pubmed/29326299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gr.223891.117
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky